The aim of this study was to describe the use of thalidomide in the treatment of prurigo nodularis Hyde (PNH) refractory to other treatments or in cases where other treatments cannot be used due to side effects. 77 medical records were retrospectively reviewed for the following data: sex, age, age at the beginning of thalidomide treatment, dermatological diagnosis, duration of the skin disease, previous treatments, indications for treatment with thalidomide, effect of treatment, duration of treatment with thalidomide, reasons for cessation of thalidomide treatment, and side effects. 54 patients had PNH. All patients were refractory to standard therapy or had side effects to treatment. 42 patients were treated with thalidomide and the majority of patients experienced clinical improvement. The most common reason for discontinuation of therapy was side effects, the most frequent being peripheral neuropathy and sedation. Thalidomide effectively treats PNH refractory to standard medications. However, physicians must be aware of possible side effects, especially peripheral neuropathy.

Keywords:
Prurigo nodularis Hyde, Thalidomide, Peripheral neuropathy
1.
Rosenbach M, Werth VP: Dermatologic therapeutics: thalidomide. A practical guide. Dermatol Ther 2007;20:175–186.
2.
Somers GF: Pharmacological properties of thalidomide (α-phthalimido glutarimide), a new sedative hypnotic drug. Br J Pharmacol 1960;15:111–116.
3.
Sharma NL, Sharma VC, Mahajan VK, et al: Thalidomide: An experience in therapeutic outcome and adverse reactions. J Dermatolog Treat 2007;18:335–340.
4.
Tseng S, Pak G, Washenik K, et al: Rediscovering thalidomide: A review of its mechanism of action, side effects and potential uses. J Am Acad Dermatol 1996;35:969–979.
5.
Cavaletti G, Beronio A, Reni L, et al: Thalidomide sensory neurotoxicity. A clinical and neurophysiologic study. Neurology 2004;62:2291–2293.
6.
Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G: Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med 2002;1:412–413.
7.
Bastuji-Garin S, Ochonsky S, Bouche P, Gheradi RK, Duguet C, Djerradine Z, Poli F, Revuz J: Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002;119:1020–1026.
8.
Doherty SD, Hsu S: A case series of 48 patients treated with thalidomide. J Drugs Dermatol 2008;7:769–773.
9.
Faver IR, Guerra SG, Su WPD, El-Azhary R: Thalidomide for dermatology: a review of clinical uses and adverse effects. Int J Dermatol 2005;44:61–67.
10.
Radomsky CL, Levine N: Thalidomide. Dermatol Clin 2001;19:87–103.
11.
Moraes M, Russo G: Thalidomide and its dermatologic uses. Am J Med Sci 2001;321:321–326.
12.
Wines NY, Cooper AJ, Wines MP: Thalidomide in dermatology. Australas J Dermatol 2002;43:229–238.
13.
Nasca MR, Micali G, Cheigh NH, West LE, West DP: Dermatologic and nondermatologic uses of thalidomide. Ann Pharmacother 2003;37:1307–1320.
14.
Laffitte E, Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf 2004;3:47–56.
15.
Paghdal KV, Schwartz R: Thalidomide and its dermatologic uses. Acta Dermatovenerol Croat 2007;15:39–44.
16.
Chen M, Doherty SD, Hsu S: Innovative uses of thalidomide. Dermatol Clin 2010;28:577–586.
17.
Wolkenstein P, Latarjet J, Roujeau JC, et al: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586–1589.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.